| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We explored treatment / prevention methods by clarifying pathologically and molecular biologically the biological properties of tumor developed in glucagon gene knockout mouse in which pancreatic tumors arose spontaneously. We reported that the pancreatic tumor developed in this mouse closely resembles histological and biological attitudes to human pancreatic neuroendocrine tumor (pNET). Expression of cellular growth factors and angiogenic factors (AKT, mTOR, VEGF, etc.) in pancreatic islet cells at each stage of the process of malignant transformation were examined by immunostaining of excised tissue specimens. Everolimus, an mTOR inhibitor which has clinical indication for pNET, was continued to be administered to these mice shortly after birth, and it was confirmed that pancreatic tumor development was suppressed.
|
